Examples of using Vancomycin in English and their translations into Vietnamese
{-}
-
Colloquial
-
Ecclesiastic
-
Computer
MRSA/ORSA is treated using vancomycin.
Vancomycin solution is injected intravenously.
Cholestyramine has been shown to bind vancomycin in-vitro.
Vancomycin resistant enterococci infections can produce mortality rates of between 42 and 81%.
Dalbavancin is a lipoglycopeptide belonging in the same glycopeptide class as vancomycin.
Vancomycin Hydrochloride for Injection should be administered in a diluted solution over a period of not less than 60 minutes to avoid rapid-infusion-related reactions.
In studies of normal volunteers,infusion-related events did not occur when vancomycin was administered at a rate of 10 mg/min or less.
The vancomycin dosage for intrapartum GBS prophylaxis should be based on weight and baseline renal function(20 mg/kg intravenously every 8 hours, with a maximum of 2 gm per single dose.).
Hematopoietic: Reversible neutropenia,usually starting 1 week or more after onset of intravenous therapy with vancomycin or after a total dose of more than 25 g, has been reported for several dozen patients.
Treatment with vancomycin is successful in approximately 49% of people.[1] Linezolid belongs to the newer oxazolidinone class of antibiotics which has been shown to be effective against both CA-MRSA and HA-MRSA.
Scientists from the London Centre for Nanotechnology(LCN) at UCL are using anovel nanomechanical approach to investigate the workings of vancomycin, one of the few antibiotics that can be used to combat increasingly resistant infections such as MRSA.
Vancomycin shall only be administered as slow intravenous infusion of at least one hour duration or at a maximum rate of 10 mg/min(whichever is longer) which is sufficiently diluted(at least 100 ml per 500 mg or at least 200 ml per 1000 mg).
Acquired resistance to glycopeptides is most common in enterococci and is based on acquisition of various van gene complexes which modifies the D-alanyl-D-alanine target to D-alanyl-D-lactate orD-alanyl-D-serine which bind vancomycin poorly.
The combination of Vancomycin with amphotericin B, cisplatin, aminoglycosides, diuretics, cyclosporine, polymyxins increases side effects from the kidneys and hearing organs, up to severe kidney damage and hearing loss;
Hematocrit(if low, the mother receives iron supplements) Group B Streptococcus screen. If positive, the woman receives IV penicillin or ampicillin while in labor- or, if she is allergic to penicillin, an alternative therapy,such as IV clindamycin or IV vancomycin.
Vancomycin shall only be administered as slow intravenous infusion of at least one hour duration or at a maximum rate of 10 mg/min(whichever is longer) which is sufficiently diluted(at least 100 ml per 500 mg or at least 200 ml per 1000 mg).
Moreover, the first randomized controlled trial for FMT for this purpose was published this year and showed that FMT was significantlymore effective than a standard antibiotic course of vancomycin for the treatment of recurrent Clostridium difficile associated diarrhea.
In addition, the Committee reviewed the recommended dosage for vancomycin for the various indications and patient groups, and concluded that the starting dose of vancomycin by infusion should be calculated according to the age and weight of the patient.
In patients with severe renal impairment(creatinine clearance below 20 ml/min) or those on renal replacement therapy, the appropriate timing and amount of subsequent doses largely depend on the modality of RRT andshould be based on serum vancomycin trough levels and on residual renal function.
The researchers focused on two of the most dangerous MDROs- vancomycin resistant Enterococcus(VRE), and methicillin-resistant Staphylococcus aureus(MRSA)- as well as four Gram-negative bacteria that have evolved resistance to two powerful antibiotics.
Similarly, concomitant use with nephrotoxic agents such as aminoglycoside antibiotics, NSAIDs(e.g., ibuprofen for closure of patent ductus arteriosus) or amphotericin B is associated with an increased risk of nephrotoxicity andtherefore more frequent monitoring of vancomycin serum levels and renal function is indicated.
Vancomycin is a drug known as a last resort to fight blood infections and pneumonia, caused by staphylococcus bacteria that are becoming obsolete, resistant bacteria that have developed in Animal animals use drugs that contain growth stimulating hormones.
Mutual enhancement of action is observed with the simultaneous use of Ampiox with bactericidal antibiotics,including vancomycin, rifampicin, cephalosporins and aminoglycosides, mutual weakening- when used with macrolides, tetracyclines, linkosamides, sulfanilamides, chloramphenicol.
In 1996, vancomycin resistance was reported in Japan.[3]: 637 In many countries, outbreaks of MRSA infection were reported to be transmitted between hospitals.[4]: 402 The rate had increased to 22% by 1995, and by 1997 the percent of hospital S. aureus infections attributable to MRSA had reached 50%.
The overall rate of adverse events was comparable between the two treatment groups(The CANVAS I andCANVAS II trials evaluated ceftaroline monotherapy versus vancomycin plus aztreonam in adult patients with complicated skin and skin structure infections caused by Gram-positive and Gram-negative bacteria.).
The Infectious Disease Society of America recommends vancomycin, linezolid, or clindamycin(if susceptible) for treating those with MRSA pneumonia.[4] Ceftaroline, a fifth-generation cephalosporin, is the first beta-lactam antibiotic approved in the US to treat MRSA infections in skin and soft tissue or community acquired pneumonia.
The study also met its exploratoryendpoint of global cure(77.7% for fidaxomicin vs. 67.1% for vancomycin).[11] Clinical cure was defined as patients requiring no further therapy for the treatment of'Clostridium difficile infection two days after completion of study medication.
The first documented strain with complete(gt;16 μg/ml) resistance to vancomycin, termed vancomycin-resistant S. aureus(VRSA) appeared in the United States in 2002.[93] However, in 2011, a variant of vancomycin has been tested that binds to the lactate variation and also binds well to the original target, thus reinstating potent antimicrobial activity.
In patients with multiple recurrences,consideration may be given to treat the current episode of CDI with vancomycin, 125 mg four times daily for 10 days followed by either tapering the dose, i.e., gradually decreasing it until 125 mg per day or a pulse regimen, i.e., 125-500 mg/day every 2-3 days for at least 3 weeks.
Selective decontamination of the oropharynx(using local forms of gentamycin, colistin and vancomycin cream) or the entire gastrointestinal tract(using polymyxin, aminoglycosides or quinolone and/ or nystatin, or amphotericin) appears to be also effective, although it may increase the risk of colonization by resistant organisms.